Priority 3 from the Neurodevelopmental Disorders Canada PSP
| UNCERTAINTY: Which biological treatments (including medications, gene therapy, stem cell therapy, etc.) are effective for neurodevelopmental disorders and associated symptoms? (JLA PSP Priority 3) | |
|---|---|
| Overall ranking | 3 |
| JLA question ID | 0056/3 |
| Explanatory note | This question encompasses what treatments such as medication as well as less traditional treatments such as gene therapy, stem cell therapy, fecal transplant, or hormonal supplements, are effectivie for individuals, and for improving symptoms. This question also includes determining what group of individuals may benefit most from a particular 'biological treatment'. *Note: in the final workshop, it wasd disscussed that cannabis products could be investigated as part of this question |
| Evidence | Systematic reviews: 1) James S, Stevenson SW, Silove N, Williams K. Chelation for autism spectrum disorder (ASD). Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD010766. DOI: 10.1002/14651858.CD010766.pub2.; 2) Xiong T, Chen H, Luo R, Mu D. Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD010922. DOI: 10.1002/14651858.CD010922.pub2.; 3) Rueda JR, Guillén V, Ballesteros J, Tejada MI, Solà I. L-acetylcarnitine for treating fragile X syndrome. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD010012. DOI: 10.1002/14651858.CD010012.pub2.; |
| Health Research Classification System category | Mental Health |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | Research into genetic therapies?~ What are effective biological treatments for autism?~ What is the role of stem research for Down syndrome? |
| Submitted by | Mostly family members/carers |
| PSP information | |
|---|---|
| PSP unique ID | 0056 |
| PSP name | Neurodevelopmental Disorders (Canada) |
| Total number of uncertainties identified by this PSP. | 63 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 28 September 2017 |